BiotechTube

MK-0524A + ER Niacin + Placebo

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hypercholesteremia

Conditions

Hypercholesteremia, Hyperlipidemia

Trial Timeline

Jul 1, 2006 → Jan 1, 2007

NCT ID
NCT00376584

About MK-0524A + ER Niacin + Placebo

MK-0524A + ER Niacin + Placebo is a phase 3 stage product being developed by Merck for Hypercholesteremia. The current trial status is completed. This product is registered under clinical trial identifier NCT00376584. Target conditions include Hypercholesteremia, Hyperlipidemia.

What happened to similar drugs?

2 of 4 similar drugs in Hypercholesteremia were approved

Approved (2) Terminated (0) Active (2)
✅atorvastatin, LipitorAstellas PharmaApproved
✅Rosuvastatin + HMG CoA inhibitorShionogiApproved
🔄Rosuvastatin calciumAstraZenecaPhase 3
🔄Rosuvastatin + AtorvastatinAstraZenecaPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00376584Phase 3Completed

Competing Products

5 competing products in Hypercholesteremia

See all competitors
ProductCompanyStageHype Score
atorvastatin, LipitorAstellas PharmaApproved
43
Rosuvastatin + HMG CoA inhibitorShionogiApproved
43
SHR-1209 + PlaceboJiangsu Hengrui MedicinePhase 1
29
Rosuvastatin calciumAstraZenecaPhase 3
40
Rosuvastatin + AtorvastatinAstraZenecaPhase 3
40